Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President ...

In a report released on January 24, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...

Robert F. Kennedy Jr., who awaits confirmation as Donald Trump's Health and Human Services secretary, helped organize mass ...

Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...

Merck KGaA (Merck) and Opentrons Labworks have announced a partnership to automate assay kits on a ‘custom’ Opentrons Flex ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

Merck expands operations to position itself as a critical manufacturing hub in the APAC region: Our Bureau, Bengaluru Monday, January 27, 2025, 10:45 Hrs [IST] Merck has announced ...

Today's Research Daily features a real-time update on the Q4 earnings season and fresh Chevron (CVX), Merck (MRK), QUALCOMM ...

Merck, a leading science and technology company, today launched a beta version of M-Trust, a secure cyber-physical trust ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.